Key Highlights
- President Trump issued an executive directive instructing federal health agencies to accelerate psychedelic drug approval processes, igniting a sector-wide surge.
- ENVB shares rocketed over 160% during Monday’s trading session, establishing itself as a top performer among psychedelic biotechnology companies.
- The White House announced $50 million in dedicated funding for ibogaine studies, targeting PTSD treatment despite its Schedule I classification.
- Compass Pathways (CMPS) climbed 26.1%, AtaiBeckley (ATAI) jumped 28.1%, and GH Research (GHRS) advanced nearly 20% on the news.
- RBC’s Brian Abrahams characterized the directive as “a substantial step towards diminishing regulatory risk” across the psychedelic therapeutics industry.
The psychedelic biotech sector experienced a dramatic rally Monday following President Trump’s weekend announcement of an executive order commanding federal health authorities to expedite approval procedures for psychedelic-derived therapies. Leading the sector’s explosive performance was Enveric Biosciences (ENVB), which closed trading with an astonishing gain exceeding 160% — a remarkable surge for a company carrying a market capitalization of merely $3.43 million.
Enveric Biosciences, Inc., ENVB
The presidential directive wasn’t company-specific. Rather, it represented a sweeping instruction to the FDA and associated agencies to eliminate bureaucratic obstacles surrounding psychedelic medication authorizations. Nevertheless, this announcement proved sufficient to propel virtually every stock in the sector sharply higher.
AtaiBeckley (ATAI) surged 28.1% during premarket hours. Compass Pathways (CMPS) rose 26.1%. Definium Therapeutics (DFTX) advanced 14.6%. GH Research (GHRS) climbed 19.7%. The enthusiasm rippled through the entire segment rapidly.
White House Commits $50M to Ibogaine Research
Complementing the executive directive, Trump announced a $50 million commitment specifically for ibogaine research initiatives. Ibogaine represents a psychoactive substance extracted from an African plant species and currently maintains Schedule I classification under U.S. law — designating it as having no accepted medical applications at the federal level.
This substantial financial commitment indicates a meaningful transformation in the administration’s approach to mental health treatment, particularly regarding post-traumatic stress disorder. Preliminary research has demonstrated ibogaine’s potential effectiveness in addressing PTSD, especially within veteran populations.
Compass CEO Kabir Nath publicly embraced the executive action, stating it “recognizes the profound urgency of the mental health crisis facing millions of Americans.” RBC analyst Brian Abrahams reinforced this sentiment, characterizing the directive as “a substantial step towards diminishing regulatory risk” for companies developing psychedelic-based medications.
ENVB’s explosive performance arrived with important background. Just days before the announcement, the company finalized a $5 million private placement transaction — a capital raise exceeding the firm’s total market capitalization at that time. The offering included 2,222,223 shares priced at $2.25 apiece, accompanied by two warrant series valued at $2.00 per share.
Enveric’s Development Pipeline and Intellectual Property Advances
The company’s primary drug candidate, EB-003, engages 5-HT2A and 5-HT1B receptors and is under development for treating psychiatric and neurological disorders. Recently published mechanistic data demonstrated that EB-003 triggers dual signaling pathways associated with antidepressant and anti-anxiety therapeutic effects.
ENVB has also secured a U.S. patent protecting its EVM301 molecular compounds, which encompass EB-003, alongside Canadian trademark approvals for five proprietary marks including “Enveric” and “Next Generation Mental Health.”
Should both warrant series from the private placement reach full exercise, the company stands to generate an additional $8.9 million in gross capital.
Monday’s explosive 160%+ price movement reflected both the powerful sector-wide momentum generated by the executive order and the company’s recent capital raise, which extended its operational runway just as this catalytic moment arrived.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
